STOCKS TELEGRAPH

Category: Morning News

  • Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light

    Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light

    The stock price of Scienture Holdings, Inc. (NASDAQ: SCNX) saw a significant increase, rising 23.79% to $3.07 during pre-market activity. This spike comes after a major regulatory change involving one of its medications.

    FDA Gives Arbli Oral Suspension Approval

    The FDA has approved SCN-102, a losartan potassium oral suspension (10 mg/mL) produced by Scienture, LLC, a fully owned subsidiary of Scienture Holdings (SCNX), to be sold under the brand name Arbli.

    Arbli is used to treat hypertension in patients six years of age and older, manage diabetic nephropathy in some patients with type 2 diabetes, and lower the risk of stroke in those with hypertension and left ventricular hypertrophy. However, Arbli is the first ready-to-use oral liquid version of losartan that has received FDA approval and is offered for sale in the United States.

    A New Composition for Improved Patient Comfort

    Arbli is a patented development in losartan medication that provides a customized liquid formulation for patients who need or want an alternative to tablets. Arbli guarantees precise dosage, safety, and consistency by doing away with the necessity for tablet crushing and impromptu compounding. The product has secured two patents from the U.S. Patent and Trademark Office (USPTO), which are anticipated to be listed in the FDA’s Orange Book.

    Market Impact and Future Prospects

    One of the most often recommended medications for hypertension is still losartan, an angiotensin receptor blocker (ARB). The only formulations currently on the market are solid oral dose forms, which medical professionals frequently combine to create liquid solutions. Arbli distinguishes itself as the first commercially available liquid formulation requiring no additional preparation while offering extended shelf stability at room temperature.

    According to IQVIA data (MAT December 2024), losartan recorded total annual U.S. sales of approximately $292 million with 68 million prescriptions issued. The approval of Arbli underscores Scienture’s strategic focus on developing high-value pharmaceutical products tailored to underserved patient needs.

    With this milestone marking its first FDA-approved proprietary brand, Scienture (SCNX) plans to launch Arbli commercially in Q3 2025, broadening its portfolio of specialty treatments.

  • Aditxt (ADTX) Stock Rises Sharply In Pre-Market As Investors React To New Strategy

    Aditxt (ADTX) Stock Rises Sharply In Pre-Market As Investors React To New Strategy

    Aditxt, Inc. (NASDAQ: ADTX) saw a sharp rise in its stock value after announcing key strategic initiatives. As of the latest pre-market check, ADTX shares were trading at $6.12, up 40.05%, reflecting strong investor confidence.

    Advancements in Clinical Trials and Regulatory Efforts

    Aditxt provided a corporate update highlighting progress across its subsidiaries. Adimune Inc. is advancing toward clinical trials, having shipped drug substances for ADI-100. It is preparing an Investigational New Drug (IND) application for Stiff Person Syndrome (SPS) in partnership with the Mayo Clinic and a Clinical Trial Application for Type 1 Diabetes (T1D) and Psoriasis in Germany. Clinical trials for these conditions are planned in both Germany and the U.S.

    Pearsanta Prepares for IPO and Commercial Launch

    Pearsanta, Inc., Aditxt’s precision diagnostics subsidiary, is set for a commercial launch in late 2025, starting with blood-based tests for Prostate Cancer and Endometriosis. The company has engaged Dominari Securities LLC as the lead underwriter for its planned IPO, aiming to fund commercialization and expand its Mitomic Technology platform for early cancer detection. A randomized controlled study for the Mitomic Prostate Test is also in progress.

    Adivue Focuses on Neurological Monitoring

    Following its acquisition of Brain Scientific assets, Aditxt is launching commercialization efforts through its subsidiary, Adivue, Inc. Adivue is working toward FDA re-approval of Brain Scientific’s electroencephalogram (EEG) device and establishing strategic partnerships for product development and commercial launch.

    Strategic Partnerships and Business Expansion

    Aditxt has extended its agreement with Appili Therapeutics, Inc. through March 2025, completing the required $250,000 payments. The company is also evaluating additional opportunities with Appili. Similarly, ADTXand Evofem Biosciences, Inc. continue discussions on integrating Evofem into Aditxt’s business acceleration platform.

    Commitment to Transparency with Weekly Updates

    To enhance communication, the company is launching the Aditxt Weekly Update series on March 21, 2025. The first session will feature a discussion between CEO Amro Albanna and Saundra Pelletier, offering insights into corporate strategy and future plans.

    ADTX remains focused on advancing subsidiaries toward key milestones while executing its acquisition strategy, reinforcing its commitment to innovation and growth.

  • FDA Lifts Clinical Hold, vTv Therapeutics (VTVT) Stock Surges

    FDA Lifts Clinical Hold, vTv Therapeutics (VTVT) Stock Surges

    Shares of vTv Therapeutics Inc. (NASDAQ: VTVT) are on a significant surge today following the lifting of a clinical hold on a key trial. As of the most recent market check, VTVT stock was soaring 64.75%, trading at $24.42.

    FDA Clears Cadisegliatin Clinical Program

    The FDA has removed the clinical hold on vTv Therapeutics’ cadisegliatin clinical program, which includes the CATT1 Phase 3 study for type 1 diabetes (T1D), the company stated. Cadisegliatin is a liver-selective glucokinase activator that is taken orally. It has been shown to have good tolerability in more than 500 patients, and therapy can last up to six months.

    After a chromatographic signal was found in a human absorption, distribution, metabolism, and excretion (ADME) study of cadisegliatin, the regulatory hold was first put in place on July 26, 2024. The trial was temporarily halted due to this abnormality, which was not resolvable with conventional mass spectroscopy methods.

    Resolution and Resumption of the Trial

    At the time of the clinical hold, no patients had been administered doses in the CATT1 trial, and prior clinical investigations had not identified any safety concerns. Following an extensive review, vTv Therapeutics submitted a comprehensive response letter, concluding that the chromatographic signal was an experimental artifact. As a result, on March 14, 2025, the FDA formally removed the hold.

    With a revised protocol, vTv Therapeutics now intends to restart the study with a shorter period of six months instead of twelve. The purpose of this modification is to expedite the production of topline data and make it easier to begin bigger pivotal studies that are required for a subsequent New Drug Application (NDA) filing.

    There will be no changes to the primary endpoint, which evaluates level 2 and level 3 hypoglycemia rates at six months. However, the extended six-month safety data collection period will be omitted.

    Possible Advancement in the Management of Diabetes

    With the restart of the CATT1 study, vTv Therapeutics is still assessing how well cadisegliatin works with insulin treatment to improve glycemic control and lower the incidence of hypoglycemia. If cadisegliatin is effective, it may be the first oral adjunctive medication for type 1 diabetes, which would represent a major improvement in the treatment of the disease.

  • Richtech Robotics (RR) Sees Market Boost Amid Global Exhibition

    Richtech Robotics (RR) Sees Market Boost Amid Global Exhibition

    Shares of Richtech Robotics Inc. (NASDAQ: RR) were surging 19.58% as of the last check today, reaching $2.02. The sharp increase coincides with RR’s participation in ProWein 2025, a premier global trade fair for the wine and spirits industry. The Nevada-based developer of AI-driven service robots is showcasing its latest innovations at the event, reinforcing its commitment to international expansion.

    At ProWein 2025, Richtech Robotics Displays AI Innovation

    Richtech Robotics is attending ProWein 2025, scheduled for March 16–18 in Düsseldorf, Germany. RR is showcasing its cutting-edge robotic solutions designed specifically for the wine and spirits sector at Hall 5, Booth 5E46.

    Known as the only trade show that covers the whole world of wine and spirits, ProWein anticipates more than 5,200 exhibitors from more than 60 countries, as well as an anticipated 47,000 attendees.

    Scorpion: Revolutionizing Beverage Service with AI

    At the event, Richtech Robotics is introducing its Scorpion service solution, an AI-powered robotic arm designed to revolutionize bartending. The Scorpion platform, integrated with NVIDIA AI technology, is capable of crafting cocktails, conducting guided wine tastings, and delivering personalized beverage recommendations based on customer preferences.

    With its ability to adapt to environmental changes and perform tasks with precision, Scorpion mirrors human-like service, making it a valuable asset for businesses facing labor shortages in the food and beverage sector.

    International Growth and Industry Effects

    Richtech Robotics sees its involvement at ProWein as a big step toward breaking into international markets. Robotic automation is becoming more and more popular in the hotel industry as European companies face manpower issues that are comparable to those in the United States.

    A strategic chance to interact with business executives and possible partners is provided by showcasing Scorpion’s skills at one of the most significant trade shows in the globe. By serving five liquors and five wines during the event, Scorpion is demonstrating its versatility while engaging with guests, offering in-depth product insights, and simulating the experience of a professional sommelier.

    Over 300 robotic systems have already been implemented nationwide by Richtech Robotics, which serves customers including Sodexo, Hilton, Golden Corral, and Globe Life Field, home of the Texas Rangers. RR keeps pushing the limits of AI-driven automation in the hotel industry and beyond with its growing portfolio.

  • Breakthrough Approval Sends Monogram Technologies (MGRM) Shares Soaring

    Breakthrough Approval Sends Monogram Technologies (MGRM) Shares Soaring

    As of the most recent market update, shares of Monogram Technologies Inc. (NASDAQ: MGRM) have risen 50.21% to $3.50, indicating a notable upsurge. This increase comes after a crucial regulatory approval that sets up the business for growth in the orthopedic robotics industry.

    MGRM Got Regulatory Approval for Robotic Knee

    The U.S. Food and Drug Administration (FDA) has given Monogram Technologies’ Monogram mBôs TKA System 510(k) certification, the company stated in a press release today. The Federal Food, Drug, and Cosmetic Act’s general controls provisions permit the corporation to sell the device as a result of this regulatory clearance. The accomplishment is the result of years of intensive testing, research, and development to improve robotically assisted complete knee replacement.

    Using Innovation to Advance Orthopedic Robotics

    The Monogram mBôs TKA System’s approval demonstrates MGRM’s dedication to orthopaedic innovation. The intricacy of the system, which combines precise robots with patient-specific imaging and navigation systems, made the licensing process especially difficult.

    MGRM has proven its great product-market fit by overcoming these regulatory obstacles, and it is now in a good position to shape the direction of robotically assisted orthopedic surgeries. The business is now concentrating on commercialization after reaching this milestone.

    The adoption and deployment of this cutting-edge technology will be greatly aided by strategic improvements in corporate processes and more extensive conversations with industry stakeholders. The system is designed to provide improved safety, accuracy, and efficiency, which makes it a strong option in a sector that is underserved yet changing quickly.

    Strategic Roadmap for Market Expansion

    Looking ahead, Monogram Technologies aims to integrate additional enhancements into the cleared mBôs TKA System, including recent upgrades to the cutting system. In order to gain clinical experience and verify the benefits of the technology in actual surgical settings, the business intends to work with top surgeons in strategic geographic areas.

    In order to further solidify its position as a game-changing force in the medical robotics industry, Monogram Technologies plans to extend its robotic technology beyond knee replacement to handle a variety of orthopedic applications. As it advances the future of customized robotic surgery, the FDA approval represents a watershed and presents MGRM with important local and worldwide potential.

  • Acquisition Bid Sparks Major Gains For Guess (GES) Stock

    Acquisition Bid Sparks Major Gains For Guess (GES) Stock

    After an acquisition offer to take Guess?, Inc. (NYSE: GES) private, the company’s shares saw a significant increase. The stock of GES was trading at $12.16 as of the most recent market check, which is a significant 25.36% gain.

    Proposed Transaction and Financial Backing

    Through its subsidiary, WHP Investments, LLC, WHP Global has formally submitted a non-binding purchase bid to GUESS’ Board of Directors. WHP Global plans to pay $13.00 per share in cash for all of GES’ outstanding shares under the terms of the proposal.

    According to the offer, a combination of third-party debt financing and equity investment would be used to finance the proposed deal. Furthermore, it makes the assumption that important stakeholders—known as the Proposed Rollover Shareholders—will participate in reinvestment or rollover. WHP Global intends to keep Guess? on course in terms of both strategy and operations, making sure that the company’s present business model is not significantly altered.

    Guess? has formed a Special Committee made up of impartial, independent members of its Board of Directors to carefully review the idea. The committee is assessing the offer under the direction of outside legal and financial counsel in order to decide on the appropriate course of action that will best serve the interests of shareholders.

    Strategic Partnerships Strengthen Business Outlook

    Guess? recently announced a major cooperation with WHP Global and Signal Brands in addition to the acquisition bid. The development and growth of Rag & Bone’s handbags and small leather goods category are the main objectives of the five-year license deal.

    Since its beginnings in New York in 2002, rag & bone has earned recognition in the American fashion business, merging traditional workmanship with current cultural themes. It is anticipated that this collaboration would further accelerate the brand’s growth trajectory by utilizing Signal Brands’ experience and market knowledge. Signal Brands has been a Guess? licensee since 1990.

    Long-Term Goals for Growth

    Signal Brands has strengthened its position as a worldwide leader in the handbag industry by extending its partnership with Guess? for a further 15 years. The business sees the combination as a strategic asset that will boost design innovation and market expansion after acquiring Rag & Bone. According to industry commentators, these changes may put GES in a position for long-term growth in the face of shifting market conditions.

  • Sonoma Pharmaceuticals (SNOA) Gains In Pre-Hour Trading

    Sonoma Pharmaceuticals (SNOA) Gains In Pre-Hour Trading

    Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares were rising 11.90% to $3.95 as of this morning’s last pre-market check. SNOA has made a number of encouraging announcements in the last week, which have led to this notable increase in stock value.

    New MHRA Registrations Signal the UK Market’s Growth

    The Medicines & Healthcare medicines Regulatory Agency (MHRA) recently granted Sonoma Pharmaceuticals permission to register its production facility and five important medicines in the UK. The recently authorized goods include a skin exfoliator, wound hydrogel, a variety of scar management solutions, and a wound irrigation solution based on hypochlorous acid.

    With this registration, Sonoma will be able to reach a wider audience and increase its market share in the UK by introducing its cutting-edge Microcyn-based products. The business was excited about the prospects for expansion this clearance offers in the dermatology and wound care industries.

    Adopting EU Medical Device Regulations with Success

    Sonoma Pharmaceuticals has accomplished a significant regulatory milestone in Europe in addition to registering in the UK. Four of the company’s products were successfully converted to conform to the Medical Device Regulation (MDR) of the European Union. These consist of Pediacyn for atopic dermatitis, Microdacyn60 Wound Care, Microdacyn60 Hydrogel, and the scar gel Epicyn.

    Strict requirements for the performance and safety of medical devices are mandated by the MDR, which took the place of the old Medical Device Directive in 2017. A noteworthy accomplishment is Sonoma’s early adherence to these new rules, which guarantees that its goods will satisfy all safety and legal criteria before the December 2028 date.

    Evidence of Regulatory Readiness and Product Safety

    Sonoma’s dedication to product safety and regulatory vigilance is demonstrated by the successful registration and classification of its products as Class IIb medical devices in Europe. The company’s solid clinical data and capacity to adjust to changing international requirements are clearly demonstrated by the shift to MDR compliance.

  • NanoVibronix (NAOV) Stock Surges In Pre-Market Trading Following A Positive Study

    NanoVibronix (NAOV) Stock Surges In Pre-Market Trading Following A Positive Study

    The share price of NanoVibronix, Inc. (NASDAQ: NAOV) increased significantly during pre-market trading, going up 79.82% to $3.92 as of the last check. The notable increase follows the publication of a successful independent study evaluating the company’s primary medical product, UroShield, by the Australian and New Zealand Continence Journal.

    An independent Validates UroShield’s Effectiveness

    The study highlights the device’s efficacy in reducing catheter-associated urinary tract infections (CAUTIs) and its potential for widespread clinical use among patients with indwelling urinary catheters (IUCs). UroShield customers showed encouraging outcomes from the independent health service research showing that Catheter blockages reduced by 70% while Catheter changes decreased by 52.3%.

    The positive impact of the device on patient care is further supported by the fact that clinicians saw less catheter-related interventions and more patient comfort. The study also discovered that UroShield decreased nursing effort and produced measurable cost savings for medical professionals.

    Better Patient Results and Cost Effectiveness

    The effectiveness of UroShield in a New Zealand District Nursing Service was described in depth in the published study, which also highlighted how it improves the quality of life for patients with IUCs. UroShield dramatically decreased catheter-associated infections and obstructions, resulting in fewer medical interventions and improved patient comfort, according to the Quality Improvement initiative.

    Furthermore, during a five-month period, the final cost analysis showed a 63.5% drop in resource consumption, mostly as a result of fewer medical interventions and emergency call-outs.

    Devices of the Future in Development

    Along with the encouraging trial findings, NanoVibronix recently reported that the design process for its next PainShield and UroShield devices was finished. In December 2024, a third-party contractor completed the creation of the prototype with an emphasis on lowering assembly costs, minimizing risk factors, and improving user ease.

    These advancements show NanoVibronix’s continuous efforts towards innovation in medical technology and supporting its prospects for further market expansion and acceptance. With these developments, NAOV is securing its position in the healthcare sector by offering innovative solutions to improve patient care and operational efficacy.

  • Pre-Market Momentum: Exicure (XCUR) Shares Rise After Key Approval

    Pre-Market Momentum: Exicure (XCUR) Shares Rise After Key Approval

    Shares of Exicure, Inc. (NASDAQ: XCUR) rose 4.59% to $13.66 during premarket trading. This rise follows the company’s announcement that it has been granted a new patent by the Australian Patent Office, strengthening its position in the study of cancer treatments.

    Patent Strengthens Cancer Treatment Strategy

    Exicure has been granted a patent for “GPCR Heteromer Inhibitors and Uses Thereof,” protecting its innovative approach to cancer treatment that targets GPCRx and CXCR4. The company’s Phase 2 clinical study, which evaluates the combined effectiveness of GPC-100 and propranolol for patients with multiple myeloma, is supported by this patent.

    By strengthening its top clinical program and opening the door for additional potent treatment options, the recently granted patent expands Exicure’s intellectual property protection.

    By concurrently targeting CXCR4 and ADRB2, the study aims to increase hematopoietic stem cell mobility and boost the efficacy of CXCR4 inhibitors such as GPC-100. Taiwan, Japan, and the United States have previously awarded similar patents, while other applications are still pending in important international markets.

    Purchasing GPCR Therapeutics USA Strategically

    Through a Share Purchase Agreement, Exicure has strategically purchased GPCR Therapeutics USA Inc., a California-based subsidiary of GPCR Therapeutics Inc., a Korean company. Concurrent with the agreement’s execution, the purchase was completed, adding GPCR USA to XCUR’s portfolio.

    A Licensing Agreement Increases Efforts at Commercialization

    Exicure and GPCR Therapeutics Inc. signed a License and Collaboration Agreement (L&C Agreement) after the purchase. As per this arrangement, XCUR is in charge of advancing and bringing GPCR-related technology to market. According to the agreements, milestone payments must be linked to significant sales, clinical, and regulatory accomplishments.

    Furthermore, Exicure shall pay recurrent royalties on net sales from the licensed technology at a minimum rate of 10%. XCUR continues to solidify its place in the biotechnology industry by promoting cutting-edge cancer treatment options with this most recent patent and strategic alliance.

  • Quantum (QMCO) Shares Climb As Company Unveils New Data Security Solution

    Quantum (QMCO) Shares Climb As Company Unveils New Data Security Solution

    Quantum Corporation (NASDAQ: QMCO) stock is on a significant uptick today after revealing its latest data protection solution. As of the latest market check, QMCO shares were surging by 32.42%, trading at $14.91. The spike follows the announcement of Quantum GO Refresh for the DXi T-Series, a new offering aimed at enhancing data security and recovery capabilities for enterprises.

    Introduction of Quantum GO Refresh for DXi T-Series

    The idea of its latest product, Quantum GO Refresh, is to give users greater options for their data security plans. This solution offers a full subscription model for the DXi T-Series all-flash backup appliances.

    Along with the extra advantage of frequent hardware upgrades as technology advances, this covers hardware, software, and support. The action is especially necessary as ransomware and other cyberattacks are becoming a bigger danger to businesses, making dependable and quick recovery options essential.

    A Flexible, Economical Subscription Model

    Quantum GO Refresh aims to make enterprise-grade data protection more accessible and predictable. By offering a pay-as-you-go subscription model, organizations can now avoid hefty upfront investments.

    With the guarantee that both software and hardware will be regularly updated, businesses instead have the freedom to grow their data protection solutions as needed. With this strategy, companies may concentrate on their expansion rather than on device lifecycles or unforeseen expenses.

    Improved Cyber Resilience and Streamlined Procurement

    The new solution addresses the limitations of traditional data protection methods, which often rely on cloud storage and HDD-based backup systems. These older systems are inefficient, slow to restore, and come with unpredictable networking and egress fees.

    Quantum GO Refresh, in contrast, offers a high-performance, on-premises solution with quick recovery times and immutable data copies stored on all-flash DXi T-Series systems. It promises a future-proof, low-cost solution that enhances cyber resilience and ensures business continuity.

    Quantum GO Refresh is now available through the company’s global network of resellers, with subscription agreements ranging from three to five years. The offering is expected to expand to other QMCO solutions later this year.